Epilepsy, which afflicts approximately 4.7 million people in the major pharmaceutical markets under study according to Clarivate epidemiology, is a heterogeneous condition requiring individualized treatment based largely on the patient’s seizure syndrome and seizure type. The epilepsy therapy market already comprises more than 25 antiepileptic drugs (AEDs), most of them generic, that can be effective for many patients. In this challenging market environment, developers increasingly target underserved, niche segments or subpopulations (e.g., orphan pediatric syndromes, rescue therapy) as a path to differentiation. Understanding the trajectory of the established epilepsy market and the evolving competitive landscape in niche segments is critical for marketers of both current and emerging brands to retain market share or carve out a clinical role.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: Approximately 29 country-specific interviews with thought-leading neurologists, supported by survey data collected for this content and other Clarivate research.
Epidemiology: Diagnosed prevalence of epilepsy by country, segmented by generalized and partial-onset seizures; drug-treated cases.
Emerging therapies: Phase III/PR: 4 drugs; coverage of select Phase II products.
Market forecast features: Patient-based market forecast extending through 2030, segmented by brands/generics.
Key companies: Aquestive Therapeutics, Bial, Eisai, Eton Pharmaceuticals, Azurity Pharmaceuticals, GW Pharmaceuticals, Lundbeck, Marinus Pharmaceuticals, Neurelis, Sanofi, SK Biopharmaceuticals, UCB, Sunovion, Zogenix.
Key drugs: Levetiracetam, lamotrigine, carbamazepine, valproates, Vimpat (lacosamide), Aptiom/Zebinix (eslicarbazepine acetate), Fycompa (perampanel), Briviact (brivaracetam), Epidiolex / Epidyolex (cannabidiol), Fintepla (fenfluramine), Xcopri / Onztory (cenobamate), Nayzilam (intranasal midazolam), Libervant (buccal diazepam), Valtoco (intranasal diazepam).
Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.